REFERENCES
3. Yu YR, Rodriguez JR. Clinical presentation of Crohn’s, ulcerative colitis, and indeterminate colitis: symptoms, extraintestinal manifestations, and disease phenotypes. Semin Pediatr Surg 2017;26:349-55.
4. Wang R, Li Z, Liu S, Zhang D. Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019. BMJ Open 2023;13:e065186.
5. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017;390:2769-78.
6. Aldars-García L, Chaparro M, Gisbert JP. Systematic review: the gut microbiome and its potential clinical application in inflammatory bowel disease. Microorganisms 2021;9:977.
8. Venegas DP, De la Fuente MK, Landskron G, et al. Corrigendum: short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front Immunol 2019;10:1486.
9. Sonnenburg ED, Sonnenburg JL. Starving our microbial self: the deleterious consequences of a diet deficient in microbiota-accessible carbohydrates. Cell Metab 2014;20:779-86.
10. Roediger WE. Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut 1980;21:793-8.
11. Couto MR, Gonçalves P, Magro F, Martel F. Microbiota-derived butyrate regulates intestinal inflammation: focus on inflammatory bowel disease. Pharmacol Res 2020;159:104947.
12. De Vadder F, Kovatcheva-Datchary P, Goncalves D, et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 2014;156:84-96.
13. Wu W, Sun M, Chen F, et al. Microbiota metabolite short-chain fatty acid acetate promotes intestinal IgA response to microbiota which is mediated by GPR43. Mucosal Immunol 2017;10:946-56.
14. Ramírez-Pérez O, Cruz-Ramón V, Chinchilla-López P, Méndez-Sánchez N. The role of the gut microbiota in bile acid metabolism. Ann Hepatol 2017;16:S21-6.
15. Duboc H, Rajca S, Rainteau D, et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut 2013;62:531-9.
16. Sinha SR, Haileselassie Y, Nguyen LP, et al. Dysbiosis-induced secondary bile acid deficiency promotes intestinal inflammation. Cell Host Microbe 2020;27:659-70.e5.
17. Singh S, Feuerstein JD, Binion DG, Tremaine WJ. AGA technical review on the management of mild-to-moderate ulcerative colitis. Gastroenterology 2019;156:769-808.e29.
18. Das KM, Farag SA. Current medical therapy of inflammatory bowel disease. World J Gastroenterol 2000;6:483-9.
19. Das KM, Eastwood MA, McManus JPA, Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 1973;289:491-5.
20. Ye B, van Langenberg DR. Mesalazine preparations for the treatment of ulcerative colitis: are all created equal? World J Gastrointest Pharmacol Ther 2015;6:137-44.
21. Kumar M, Saini V, Roy CK, Bhatt S, Malik A. Formulation development and evaluation of colon targeted beads of mesalamine. J Drug Des Res 2018;5:1067. Available from: https://www.researchgate.net/profile/Anuj-Malik-2/publication/324888491_Formulation_Development_and_Evaluation_of_Colon_Targeted_Beads_of_Mesalamine/links/5ae93d3745851588dd8174e5/Formulation-Development-and-Evaluation-of-Colon-Targeted-Beads-of-Mesalamine. [Last accessed on 25 Sep 2023]
22. Bayan MF, Bayan RF. Recent advances in mesalamine colonic delivery systems. Futur J Pharm Sci 2020;6:1-7.
23. Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-γ. J Exp Med 2005;201:1205-15.
24. Nielsen OH, Munck LK. Drug insight: aminosalicylates for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol 2007;4:160-70.
25. Braccia DJ, Minabou Ndjite G, Weiss A, et al. Gut microbiome-wide search for bacterial azoreductases reveals potentially uncharacterized azoreductases encoded in the human gut microbiome. Drug Metab Dispos 2023;51:142-53.
26. Simpson JB, Sekela JJ, Carry BS, Beaty V, Patel S, Redinbo MR. Diverse but desolate landscape of gut microbial azoreductases: a rationale for idiopathic IBD drug response. Gut Microbes 2023;15:2203963.
27. Sousa T, Yadav V, Zann V, Borde A, Abrahamsson B, Basit AW. On the colonic bacterial metabolism of azo-bonded prodrugsof 5-aminosalicylic acid. J Pharm Sci 2014;103:3171-5.
28. van Hogezand RA, Kennis HM, van Schaik A, Koopman JP, van Hees PAM, van Tongeren JHM. Bacterial acetylation of 5-aminosalicylic acid in faecal suspensions cultured under aerobic and anaerobic conditions. Eur J Clin Pharmacol 1992;43:189-92.
29. Deloménie C, Fouix S, Longuemaux S, et al. Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid. J Bacteriol 2001;183:3417-27.
30. Allgayer H, Ahnfelt NO, Kruis W, et al. Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease. Gastroenterology 1989;97:38-41.
31. Mehta RS, Mayers JR, Zhang Y, et al. Gut microbial metabolism of 5-ASA diminishes its clinical efficacy in inflammatory bowel disease. Nat Med 2023;29:700-9.
32. Sandberg-Gertzen H, Kjellander J, Sundberg-Gillå B, Järnerot G. In vitro effects of sulphasalazine, azodisal sodium, and their metabolites on Clostridium difficile and some other faecal bacteria. Scand J Gastroenterol 1985;20:607-12.
33. Liu F, Ma R, Riordan SM, et al. Azathioprine, mercaptopurine, and 5-aminosalicylic acid affect the growth of IBD-associated Campylobacter species and other enteric microbes. Front Microbiol 2017;8:527.
34. Zhang L, Lee H, Grimm MC, Riordan SM, Day AS, Lemberg DA. Campylobacter concisus and inflammatory bowel disease. World J Gastroenterol 2014;20:1259-67.
35. Zhang L. Oral Campylobacter species: initiators of a subgroup of inflammatory bowel disease? World J Gastroenterol 2015;21:9239-44.
36. Schwartz AG, Targan SR, Saxon A, Weinstein WM. Sulfasalazine-induced exacerbation of ulcerative colitis. N Engl J Med 1982;306:409-12.
37. Zhang S, Fu J, Dogan B, Scherl EJ, Simpson KW. 5-Aminosalicylic acid downregulates the growth and virulence of Escherichia coli associated with IBD and colorectal cancer, and upregulates host anti-inflammatory activity. J Antibiot 2018;71:950-61.
38. Kaufman J, Griffiths TA, Surette MG, Ness S, Rioux KP. Effects of mesalamine (5-aminosalicylic acid) on bacterial gene expression. Inflamm Bowel Dis 2009;15:985-96.
39. Dahl JU, Gray MJ, Bazopoulou D, et al. The anti-inflammatory drug mesalamine targets bacterial polyphosphate accumulation. Nat Microbiol 2017;2:16267.
40. Rao NN, Gómez-García MR, Kornberg A. Inorganic polyphosphate: essential for growth and survival. Annu Rev Biochem 2009;78:605-47.
41. Gray MJ, Wholey WY, Wagner NO, et al. Polyphosphate is a primordial chaperone. Mol Cell 2014;53:689-99.
42. Roewe J, Stavrides G, Strueve M, et al. Bacterial polyphosphates interfere with the innate host defense to infection. Nat Commun 2020;11:4035.
43. Zheng H, Chen M, Li Y, et al. Modulation of gut microbiome composition and function in experimental colitis treated with sulfasalazine. Front Microbiol 2017;8:1703.
44. Cevallos SA, Lee JY, Velazquez EM, et al. 5-aminosalicylic acid ameliorates colitis and checks dysbiotic Escherichia coli expansion by activating PPAR-γ signaling in the intestinal epithelium. mBio 2021;12:e03227-20.
45. Huang Y, Wu M, Xiao H, Liu H, Yang G. Mesalamine-mediated amelioration of experimental colitis in piglets involves gut microbiota modulation and intestinal immune cell infiltration. Front Immunol 2022;13:883682.
46. Andrews CN, Griffiths TA, Kaufman J, Vergnolle N, Surette MG, Rioux KP. Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2011;34:374-83.
47. Olaisen M, Spigset O, Flatberg A, et al. Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis. Aliment Pharmacol Ther 2019;49:1301-13.
48. Jun X, Ning C, Yang S, et al. Alteration of fungal microbiota after 5-ASA treatment in UC patients. Inflamm Bowel Dis 2020;26:380-90.
49. Targownik LE, Benchimol EI, Bernstein CN, et al. Combined biologic and immunomodulatory therapy is superior to monotherapy for decreasing the risk of inflammatory bowel disease-related complications. J Crohns Colitis 2020;14:1354-63.
50. Crohn’s and Colitis, UK. Methotrexate. 2019. Available from: https://crohnsandcolitis.org.uk/media/4qinwgmh/methotrexate-pdf.pdf. [Last accessed on 25 Sep 2023].
51. Crouwel F, Buiter HJC, de Boer NK. Gut microbiota-driven drug metabolism in inflammatory bowel disease. J Crohns Colitis 2020;15:307-15.
52. Nayak RR, Alexander M, Deshpande I, et al. Methotrexate impacts conserved pathways in diverse human gut bacteria leading to decreased host immune activation. Cell Host Microbe 2021;29:362-77.e11.
53. AlAmeel T, Al Sulais E, Raine T. Methotrexate in inflammatory bowel disease: a primer for gastroenterologists. Saudi J Gastroenterol 2022;28:250-60.
54. Dervieux T, Zablocki R, Kremer J. Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis. Rheumatology 2010;49:2337-45.
55. Sayers E, MacGregor A, Carding SR. Drug-microbiota interactions and treatment response: Relevance to rheumatoid arthritis. AIMS Microbiol 2018;4:642-54.
56. Cronstein BN, Sitkovsky M. Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases. Nat Rev Rheumatol 2017;13:41-51.
57. Nayak RR, O’Loughlin C, Fischbach M, Turnbaugh PJ. Methotrexate is an antibacterial drug metabolized by human gut bacteria. 2016. p. 1204. Available from: https://acrabstracts.org/abstract/methotrexate-is-an-antibacterial-drug-metabolized-by-human-gut-bacteria/. [Last accessed on 25 Sep 2023].
58. Levy CC, Goldman P. The enzymatic hydrolysis of methotrexate and folic acid. J Biol Chem 1967;242:2933-8.
59. Letertre MPM, Munjoma N, Wolfer K, et al. A two-way interaction between methotrexate and the gut microbiota of male sprague-dawley rats. J Proteome Res 2020;19:3326-39.
60. Mccullough JL, Chabner BA, Bertino JR. Purification and properties of carboxypeptidase G 1. J Biol Chem 1971;246:7207-13.
61. Rattu MA, Shah N, Lee JM, Pham AQ, Marzella N. Glucarpidase (voraxaze), a carboxypeptidase enzyme for methotrexate toxicity. P T 2013;38:732-44.
62. Larimer CM, Slavnic D, Pitstick LD, Green JM. Comparison of substrate specificity of Escherichia coli p-aminobenzoyl-glutamate hydrolase with Pseudomonas carboxypeptidase G. Adv Enzyme Res 2014;2:39-48.
63. Shin YS, Buehring KU, Stokstad EL. The metabolism of methotrexate in Lactobacillus casei and rat liver and the influence of methotrexate on metabolism of folic acid. J Biol Chem 1974;249:5772-7.
64. Liu J, Bolstad DB, Bolstad ESD, Wright DL, Anderson AC. Towards new antifolates targeting eukaryotic opportunistic infections. Eukaryot Cell 2009;8:483-6.
65. Greenstein RJ, Su L, Haroutunian V, Shahidi A, Brown ST. On the action of methotrexate and 6-mercaptopurine on M. avium subspecies paratuberculosis. PLoS One 2007;2:e161.
66. Pierce ES. Could Mycobacterium avium subspecies paratuberculosis cause Crohn’s disease, ulcerative colitis…and colorectal cancer? Infect Agent Cancer 2018;13:1.
67. Zhou B, Xia X, Wang P, et al. Induction and amelioration of methotrexate-induced gastrointestinal toxicity are related to immune response and gut microbiota. EBioMedicine 2018;33:122-33.
68. R R, Malic N, Menon T, Marks E, Machani S. An unusual presentation of a patient with low-dose methotrexate causing colitis and pancytopenia. Cureus 2022;14:e33062.
69. Kopytek SJ, Dyer JCD, Knapp GS, Hu JC. Resistance to methotrexate due to AcrAB-dependent export from Escherichia coli. Antimicrob Agents Chemother 2000;44:3210-2.
70. Guðmundsdóttir JS, Fredheim EGA, Koumans CIM, et al. The chemotherapeutic drug methotrexate selects for antibiotic resistance. EBioMedicine 2021;74:103742.
71. Chourpiliadis C, Aeddula NR. Physiology, glucocorticoids. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560897/. [Last accessed on 25 Sep 2023].
72. Timmermans S, Souffriau J, Libert C. A general introduction to glucocorticoid biology. Front Immunol 2019;10:1545.
73. Bruscoli S, Febo M, Riccardi C, Migliorati G. Glucocorticoid therapy in inflammatory bowel disease: mechanisms and clinical practice. Front Immunol 2021;12:691480.
74. Franzin M, Stefančič K, Lucafò M, Decorti G, Stocco G. Microbiota and drug response in inflammatory bowel disease. Pathogens 2021;10:211.
75. Dorrington AM, Selinger CP, Parkes GC, Smith M, Pollok RC, Raine T. The historical role and contemporary use of corticosteroids in inflammatory bowel disease. J Crohns Colitis 2020;14:1316-29.
76. Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis 2020;14:4-22.
77. Matsuoka K, Kobayashi T, Ueno F, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol 2018;53:305-53.
78. Al-Sanea MM, Abdel-Hafez AA, Omar FA, Youssef AF. Biotransformation studies of prednisone using human intestinal bacteria part II: anaerobic incubation and docking studies. J Enzyme Inhib Med Chem 2009;24:1211-9.
79. Yadav V, Gaisford S, Merchant HA, Basit AW. Colonic bacterial metabolism of corticosteroids. Int J Pharm 2013;457:268-74.
80. Vertzoni M, Kersten E, van der Mey D, Muenster U, Reppas C. Evaluating the clinical importance of bacterial degradation of therapeutic agents in the lower intestine of adults using adult fecal material. Eur J Pharm Sci 2018;125:142-50.
81. Tannergren C, Bergendal A, Lennernäs H, Abrahamsson B. Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment. Mol Pharm 2009;6:60-73.
82. Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman AL. Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature 2019;570:462-7.
83. Ridlon JM, Ikegawa S, Alves JMP, et al. Clostridium scindens: a human gut microbe with a high potential to convert glucocorticoids into androgens. J Lipid Res 2013;54:2437-49.
84. Cerone-McLernon AM, Winter J, Mosbach EH, Bokkenheuser VD. Side-chain cleavage of cortisol by fecal flora. Biochim Biophys Acta 1981;666:341-7.
85. Krafft AE, Winter J, Bokkenheuser VD, Hylemon PB. Cofactor requirements of steroid-17-20-desmolase and 20 α-hydroxysteroid dehydrogenase activities in cell extracts of Clostridium scindens. J Steroid Biochem 1987;28:49-54.
86. Ly LK, Rowles III JL, Paul HM, et al. Bacterial steroid-17,20-desmolase is a taxonomically rare enzymatic pathway that converts prednisone to 1,4-androstanediene-3,11,17-trione, a metabolite that causes proliferation of prostate cancer cells. J Steroid Biochem Mol Biol 2020;199:105567.
87. Huang EY, Inoue T, Leone VA, et al. Using corticosteroids to reshape the gut microbiome: implications for inflammatory bowel diseases. Inflamm Bowel Dis 2015;21:963-72.
88. Tourret J, Willing BP, Dion S, MacPherson J, Denamur E, Finlay BB. Immunosuppressive treatment alters secretion of ileal antimicrobial peptides and gut microbiota, and favors subsequent colonization by uropathogenic Escherichia coli. Transplantation 2017;101:74-82.
89. Igarashi H, Maeda S, Ohno K, Horigome A, Odamaki T, Tsujimoto H. Effect of oral administration of metronidazole or prednisolone on fecal microbiota in dogs. PLoS One 2014;9:e107909.
90. Atherly T, Rossi G, White R, et al. Glucocorticoid and dietary effects on mucosal microbiota in canine inflammatory bowel disease. PLoS One 2019;14:e0226780.
91. Krogsgaard LR, Munck LK, Bytzer P, Wildt S. An altered composition of the microbiome in microscopic colitis is driven towards the composition in healthy controls by treatment with budesonide. Scand J Gastroenterol 2019;54:446-52.
93. Guada M, Beloqui A, Kumar MNVR, Préat V, Dios-Viéitez MC, Blanco-Prieto MJ. Reformulating cyclosporine A (CsA): more than just a life cycle management strategy. J Control Release 2016;225:269-82.
94. Evirgen S, İliaz R, Akyüz F, et al. Cyclosporine therapy as a rescue treatment in steroid refractory acute severe ulcerative colitis: a real life data from a tertiary center. Turk J Gastroenterol 2022;33:463-9.
95. D'Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001;120:1323-9.
96. García-López S, Gomollón-García F, Pérez-Gisbert J. Cyclosporine in the treatment of severe attack of ulcerative colitis: a systematic review. Gastroenterol Hepatol 2005;28:607-14.
97. Laharie D, Bourreille A, Branche J, et al. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. Gut 2018;67:237-43.
98. Wu B, Tong J, Ran Z. Tacrolimus therapy in steroid-refractory ulcerative colitis: a review. Inflamm Bowel Dis 2020;26:24-32.
99. Wang J, Yadav V, Smart AL, Tajiri S, Basit AW. Stability of peptide drugs in the colon. Eur J Pharm Sci 2015;78:31-6.
100. Guo Y, Crnkovic CM, Won KJ, et al. Commensal gut bacteria convert the immunosuppressant tacrolimus to less potent metabolites. Drug Metab Dispos 2019;47:194-202.
101. Zhang Z, Liu L, Tang H, et al. Immunosuppressive effect of the gut microbiome altered by high-dose tacrolimus in mice. Am J Transplant 2018;18:1646-56.
102. Lv W, Zhang D, He T, et al. Combination of Lactobacillus plantarum improves the effects of tacrolimus on colitis in a mouse model. Front Cell Infect Microbiol 2023;13:1130820.
103. Jiang JW, Ren ZG, Lu HF, et al. Optimal immunosuppressor induces stable gut microbiota after liver transplantation. World J Gastroenterol 2018;24:3871-83.
104. Toral M, Romero M, Rodríguez-Nogales A, et al. Lactobacillus fermentum improves tacrolimus-induced hypertension by restoring vascular redox state and improving eNOS coupling. Mol Nutr Food Res 2018;62:1800033.
105. Ekberg H, van Gelder T, Kaplan B, Bernasconi C. Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation. Transplantation 2011;92:82-7.
106. Kawakami K, Inoue T, Murano M, et al. Effects of oral tacrolimus as a rapid induction therapy in ulcerative colitis. World J Gastroenterol 2015;21:1880-6.
107. Zaza G, Dalla Gassa A, Felis G, Granata S, Torriani S, Lupo A. Impact of maintenance immunosuppressive therapy on the fecal microbiome of renal transplant recipients: comparison between an everolimus- and a standard tacrolimus-based regimen. PLoS One 2017;12:e0178228.
108. O’Reilly C, O’Sullivan Ó, Cotter PD, et al. Encapsulated cyclosporine does not change the composition of the human microbiota when assessed ex vivo and in vivo. J Med Microbiol 2020;69:854-63.
109. Lin CMA, Cooles FAH, Isaacs JD. Basic mechanisms of JAK inhibition. Mediterr J Rheumatol 2020;31:100-4.
110. Liu E, Aslam N, Nigam G, Limdi JK. Tofacitinib and newer JAK inhibitors in inflammatory bowel disease-where we are and where we are going. Drugs Context 2022;11:1-17.
111. Han Q, Deng L, Zou M, et al. Anemoside B4 protects against chronic relapsing colitis in mice by modulating inflammatory response, colonic transcriptome and the gut microbiota. Phytomedicine 2022;106:154416.
112. Texler B, Zollner A, Reinstadler V, et al. Tofacitinib-induced modulation of intestinal adaptive and innate immunity and factors driving cellular and systemic pharmacokinetics. Cell Mol Gastroenterol Hepatol 2022;13:383-404.
113. Hablot J, Ferhat M, Lavelle A, et al. Tofacitinib treatment alters mucosal immunity and gut microbiota during experimental arthritis. Clin Transl Med 2020;10:e163.
114. Jang DI, Lee AH, Shin HY, et al. The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics. Int J Mol Sci 2021;22:2719.
115. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993;34:1705-9.
116. Reinecker HC, Steffen M, Witthoeft T, et al. Enhand secretion of tumour necrosis factor-alpha, IL-6, and IL-1β by isolated lamina ropria monouclear cells from patients with ulcretive cilitis and Crohn’s disease. Clin Exp Immunol 1993;94:174-81.
117. Levin AD, Wildenberg ME, van den Brink GR. Mechanism of action of anti-TNF therapy in inflammatory bowel disease. J Crohns Colitis 2016;10:989-97.
118. Peyrin-Biroulet L, Lémann M. Review article: remission rates achievable by current therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2011;33:870-9.
119. Atiqi S, Hooijberg F, Loeff FC, Rispens T, Wolbink GJ. Immunogenicity of TNF-inhibitors. Front Immunol 2020;11:312.
120. Park J, Cheon JH. Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α. Korean J Intern Med 2022;37:895-905.
121. Papamichael K, Gils A, Rutgeerts P, et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis 2015;21:182-97.
123. Brezski RJ, Jordan RE. Cleavage of IgGs by proteases associated with invasive diseases: an evasion tactic against host immunity? mAbs 2010;2:212-20.
124. Moussata D, Goetz M, Gloeckner A, et al. Confocal laser endomicroscopy is a new imaging modality for recognition of intramucosal bacteria in inflammatory bowel disease in vivo. Gut 2011;60:26-33.
125. Deveuve Q, Lajoie L, Barrault B, Thibault G. The proteolytic cleavage of therapeutic monoclonal antibody hinge region: more than a matter of subclass. Front Immunol 2020;11:168.
126. Biancheri P, Brezski RJ, Di Sabatino A, et al. Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease. Gastroenterology 2015;149:1564-74.e3.
127. Wang Y, Gao X, Ghozlane A, et al. Characteristics of faecal microbiota in paediatric Crohn’s disease and their dynamic changes during infliximab therapy. J Crohns Colitis 2018;12:337-46.
128. Zhuang X, Tian Z, Feng R, et al. Fecal microbiota alterations associated with clinical and endoscopic response to infliximab therapy in Crohn’s disease. Inflamm Bowel Dis 2020;26:1636-47.
129. Ditto MC, Parisi S, Landolfi G, et al. Intestinal microbiota changes induced by TNF-inhibitors in IBD-related spondyloarthritis. RMD Open 2021;7:e001755.
130. Ribaldone DG, Caviglia GP, Abdulle A, et al. Adalimumab therapy improves intestinal dysbiosis in Crohn’s disease. J Clin Med 2019;8:1646.
131. Effenberger M, Reider S, Waschina S, et al. Microbial butyrate synthesis indicates therapeutic efficacy of azathioprine in IBD patients. J Crohns Colitis 2021;15:88-98.
132. Seong G, Kim N, Joung JG, et al. Changes in the intestinal microbiota of patients with inflammatory bowel disease with clinical remission during an 8-week infliximab infusion cycle. Microorganisms 2020;8:874.
133. Magnusson MK, Strid H, Sapnara M, et al. Anti-TNF therapy response in patients with ulcerative colitis is associated with colonic antimicrobial peptide expression and microbiota composition. J Crohns Colitis 2016;10:943-52.
134. Monast CS, Telesco S, Li K, Hayden K, Brodmerkel C. Su1217 the role of the microbiome in clinical response to golimumab in ulcerative colitis. Gastroenterology 2016;150:S498.
135. Bazin T, Hooks KB, Barnetche T, et al. Microbiota composition may predict anti-tnf alpha response in spondyloarthritis patients: an exploratory study. Sci Rep 2018;8:5446.
136. Aden K, Rehman A, Waschina S, et al. Metabolic functions of gut microbes associate with efficacy of tumor necrosis factor antagonists in patients with inflammatory bowel diseases. Gastroenterology 2019;157:1279-92.e11.
137. Alatawi H, Mosli M, Saadah OI, et al. Attributes of intestinal microbiota composition and their correlation with clinical primary non-response to anti-TNF-α agents in inflammatory bowel disease patients. Bosn J Basic Med Sci 2022;22:412-26.
138. Ventin-Holmberg R, Eberl A, Saqib S, et al. Bacterial and fungal profiles as markers of infliximab drug response in inflammatory bowel disease. J Crohns Colitis 2021;15:1019-31.
139. Lee JWJ, Plichta D, Hogstrom L, et al. Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease. Cell Host Microbe 2021;29:1294-304.e4.
140. Yilmaz B, Juillerat P, Øyås O, et al. Microbial network disturbances in relapsing refractory Crohn’s disease. Nat Med 2019;25:323-36.
141. Wang Y, Gao X, Zhang X, et al. Microbial and metabolic features associated with outcome of infliximab therapy in pediatric Crohn’s disease. Gut Microbes 2021;13:1-18.
142. Busquets D, Oliver L, Amoedo J, et al. RAID prediction: pilot study of fecal microbial signature with capacity to predict response to anti-TNF treatment. Inflamm Bowel Dis 2021;27:S63-6.
143. Estevinho MM, Rocha C, Correia L, et al. Features of fecal and colon microbiomes associate with responses to biologic therapies for inflammatory bowel diseases: a systematic review. Clin Gastroenterol Hepatol 2020;18:1054-69.
144. Wyant T, Fedyk E, Abhyankar B. An overview of the mechanism of action of the monoclonal antibody vedolizumab. J Crohns Colitis 2016;10:1437-44.
146. Bhandari R, Ogeyingbo OD, Kareem R, et al. Efficacy and safety of vedolizumab in management of moderate to severe ulcerative colitis: a systematic review. Cureus 2021;13:e17729.
147. Ananthakrishnan AN, Luo C, Yajnik V, et al. Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases. Cell Host Microbe 2017;21:603-10.e3.
148. Scott KP, Martin JC, Chassard C, et al. Substrate-driven gene expression in Roseburia inulinivorans: importance of inducible enzymes in the utilization of inulin and starch. Proc Natl Acad Sci U S A 2011;108:4672-9.
149. Ihekweazu FD, Fofanova TY, Queliza K, et al. Bacteroides ovatus ATCC 8483 monotherapy is superior to traditional fecal transplant and multi-strain bacteriotherapy in a murine colitis model. Gut Microbes 2019;10:504-20.
150. Moschen AR, Tilg H, Raine T. IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting. Nat Rev Gastroenterol Hepatol 2019;16:185-96.
151. Scribano ML, Aratari A, Neri B, et al. Effectiveness of ustekinumab in patients with refractory Crohn’s disease: a multicentre real-life study in Italy. Therap Adv Gastroenterol 2022;15:17562848211072412.
152. Doherty MK, Ding T, Koumpouras C, et al. Fecal microbiota signatures are associated with response to ustekinumab therapy among Crohn’s disease patients. mBio 2018;9:e02120-17.
153. Yeh NL, Hsu CY, Tsai TF, Chiu HY. Gut microbiome in psoriasis is perturbed differently during secukinumab and ustekinumab therapy and associated with response to treatment. Clin Drug Investig 2019;39:1195-203.
154. Critch J, Day AS, Otley A, King-Moore C, Teitelbaum JE, Shashidhar H. Use of enteral nutrition for the control of intestinal inflammation in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2012;54:298-305.
155. Adamji M, Day AS. An overview of the role of exclusive enteral nutrition for complicated Crohn’s disease. Intest Res 2019;17:171-6.
156. Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis 2014;8:1179-207.
157. Gatti S, Galeazzi T, Franceschini E, et al. Effects of the exclusive enteral nutrition on the microbiota profile of patients with Crohn’s disease: a systematic review. Nutrients 2017;9:832.
158. MacLellan A, Moore-Connors J, Grant S, Cahill L, Langille MGI, Van Limbergen J. The impact of exclusive enteral nutrition (EEN) on the gut microbiome in Crohn’s disease: a review. Nutrients 2017;9:0447.
159. Melton SL, Taylor KM, Gibson PR, Halmos EP. Review article: Mechanisms underlying the effectiveness of exclusive enteral nutrition in Crohn’s disease. Aliment Pharmacol Ther 2023;57:932-47.
160. Horwat P, Kopeć S, Garczyk A, et al. Influence of enteral nutrition on gut microbiota composition in patients with Crohn’s disease: a systematic review. Nutrients 2020;12:2551.
161. Diederen K, Li JV, Donachie GE, et al. Exclusive enteral nutrition mediates gut microbial and metabolic changes that are associated with remission in children with Crohn’s disease. Sci Rep 2020;10:18879.
162. Quince C, Ijaz UZ, Loman N, et al. Extensive modulation of the fecal metagenome in children with Crohn’s disease during exclusive enteral nutrition. Am J Gastroenterol 2015;110:1718-29.
163. Lv Y, Lou Y, Liu A, et al. The impact of exclusive enteral nutrition on the gut microbiome and bile acid metabolism in pediatric Crohn’s disease. Clin Nutr 2023;42:116-28.
164. Jones CMA, Connors J, Dunn KA, et al. Bacterial taxa and functions are predictive of sustained remission following exclusive enteral nutrition in pediatric Crohn’s disease. Inflamm Bowel Dis 2020;26:1026-37.
165. Xiao F, Gao X, Hu H, et al. Exclusive enteral nutrition exerts anti-inflammatory effects through modulating microbiota, bile acid metabolism, and immune activities. Nutrients 2022;14:4463.
166. Jiang J, Chen L, Chen Y, Chen H. Exclusive enteral nutrition remodels the intestinal flora in patients with active Crohn’s disease. BMC Gastroenterol 2022;22:212.
167. Dunn KA, Moore-Connors J, MacIntyre B, et al. Early changes in microbial community structure are associated with sustained remission after nutritional treatment of pediatric Crohn’s disease. Inflamm Bowel Dis 2016;22:2853-62.
168. Salem GA, Selby GB. Stem cell transplant in inflammatory bowel disease: a promising modality of treatment for a complicated disease course. Stem Cell Investig 2017;4:95.
169. Kavanagh DPJ, Kalia N. Hematopoietic stem cell homing to injured tissues. Stem Cell Rev Rep 2011;7:672-82.
170. Zhang HM, Yuan S, Meng H, et al. Stem cell-based therapies for inflammatory bowel disease. Int J Mol Sci 2022;23:8494.
171. Brierley CK, Castilla-Llorente C, Labopin M, et al. Autologous haematopoietic stem cell transplantation for Crohn’s disease: a retrospective survey of long-term outcomes from the european society for blood and marrow transplantation. J Crohns Colitis 2018;12:1097-103.
172. Zama D, Biagi E, Masetti R, et al. Gut microbiota and hematopoietic stem cell transplantation: where do we stand? Bone Marrow Transplant 2017;52:7-14.
173. Ono S, Takeshita K, Kiridoshi Y, et al. Hematopoietic cell transplantation rescues inflammatory bowel disease and dysbiosis of gut microbiota in XIAP deficiency. J Allergy Clin Immunol Pract 2021;9:3767-80.
174. Metwaly A, Dunkel A, Waldschmitt N, et al. Integrated microbiota and metabolite profiles link Crohn’s disease to sulfur metabolism. Nat Commun 2020;11:4322.
175. Okamoto R, Watanabe M. Investigating cell therapy for inflammatory bowel disease. Expert Opin Biol Ther 2016;16:1015-23.
176. Bieback K, Netsch P. Isolation, culture, and characterization of human umbilical cord blood-derived mesenchymal stromal cells. In: Gnecchi M, editor. Mesenchymal stem cells. New York: Springer; 2016. p. 245-58. Available from: http://link.springer.com/10.1007/978-1-4939-3584-0_14. [Last accessed 25 Sep 2023].
177. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-7.
178. Stappenbeck TS, Miyoshi H. The role of stromal stem cells in tissue regeneration and wound repair. Science 2009;324:1666-9.
179. Ocansey DKW, Wang L, Wang J, et al. Mesenchymal stem cell-gut microbiota interaction in the repair of inflammatory bowel disease: an enhanced therapeutic effect. Clin Transl Med 2019;8:31.
180. Forbes GM, Sturm MJ, Leong RW, et al. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn’s disease refractory to biologic therapy. Clin Gastroenterol Hepatol 2014;12:64-71.
181. Dhere T, Copland I, Garcia M, et al. The safety of autologous and metabolically fit bone marrow mesenchymal stromal cells in medically refractory Crohn’s disease - a phase 1 trial with three doses. Aliment Pharmacol Ther 2016;44:471-81.
182. Zhang J, Lv S, Liu X, Song B, Shi L. Umbilical cord mesenchymal stem cell treatment for Crohn’s disease: a randomized controlled clinical trial. Gut Liver 2018;12:73-8.
183. Hu J, Zhao G, Zhang L, et al. Safety and therapeutic effect of mesenchymal stem cell infusion on moderate to severe ulcerative colitis. Exp Ther Med 2016;12:2983-9.
184. Lazebnik LB, Kniazev OV, Konopliannikov AG, et al. [Allogeneic mesenchymal stromal cells in patients with ulcerative colitis: two years of observation]. Eksp Klin Gastroenterol 2010;11:3-15.
185. Lazebnik LB, Kniazev OV, Parfenov AI, Ruchkina IN, Rogozina VA, Konopliannikov AG. [Transplantation of allogeneic mesenchymal stem cells from the bone marrow increases duration of remission and reduces the risk of ulcerative colitis relapse]. Eksp Klin Gastroenterol 2010;3:5-10.
186. Saadh MJ, Mikhailova MV, Rasoolzadegan S, et al. Therapeutic potential of mesenchymal stem/stromal cells (MSCs)-based cell therapy for inflammatory bowel diseases (IBD) therapy. Eur J Med Res 2023;28:47.
187. Soontararak S, Chow L, Johnson V, et al. Mesenchymal stem cells (MSC) derived from induced pluripotent stem cells (iPSC) equivalent to adipose-derived msc in promoting intestinal healing and microbiome normalization in mouse inflammatory bowel disease model. Stem Cells Transl Med 2018;7:456-67.
188. He R, Han C, Li Y, Qian W, Hou X. Cancer-preventive role of bone marrow-derived mesenchymal stem cells on colitis-associated colorectal cancer: roles of gut microbiota involved. Front Cell Dev Biol 2021;9:642948.
189. Yang F, Ni B, Liu Q, et al. Human umbilical cord-derived mesenchymal stem cells ameliorate experimental colitis by normalizing the gut microbiota. Stem Cell Res Ther 2022;13:475.
190. Yang F, Zheng X, Liang W, et al. Short-term clinical response and changes in the fecal microbiota and metabolite levels in patients with Crohn’s disease after stem cell infusions. Stem Cells Transl Med 2023;12:497-509.
191. Wang A, Zhang Z, Ding Q, et al. Intestinal Cetobacterium and acetate modify glucose homeostasis via parasympathetic activation in zebrafish. Gut Microbes 2021;13:1-15.
192. Xie M, Xie Y, Li Y, et al. Stabilized fermentation product of Cetobacterium somerae improves gut and liver health and antiviral immunity of zebrafish. Fish Shellfish Immunol 2022;120:56-66.
193. Cui B, Li P, Xu L, et al. Step-up fecal microbiota transplantation (FMT) strategy. Gut Microbes 2016;7:323-8.
194. Cui B, Li P, Xu L, et al. Step-up fecal microbiota transplantation strategy: a pilot study for steroid-dependent ulcerative colitis. J Transl Med 2015;13:298.
195. Ding X, Li Q, Li P, et al. Long-term safety and efficacy of fecal microbiota transplant in active ulcerative colitis. Drug Saf 2019;42:869-80.
196. Xiang L, Ding X, Li Q, et al. Efficacy of faecal microbiota transplantation in Crohn’s disease: a new target treatment? Microb Biotechnol 2020;13:760-9.
197. Park SK, Kang SB, Kim SS, et al. Additive effect of probiotics (Mutaflor) on 5-aminosalicylic acid therapy in patients with ulcerative colitis. Korean J Intern Med 2022;37:949-57.
198. Tursi A, Brandimarte G, Papa A, et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2010;105:2218-27.
199. Peng L, Zhong Y, Wang A, Jiang Z. Probiotics combined with aminosalicylic acid affiliates remission of ulcerative colitis: a meta-analysis of randomized controlled trial. Biosci Rep 2019;39:BSR20180943.
